Annual CFO
-$16.43 M
+$5.07 M+23.59%
31 December 2023
Summary:
Akari Therapeutics annual cash flow from operations is currently -$16.43 million, with the most recent change of +$5.07 million (+23.59%) on 31 December 2023. During the last 3 years, it has risen by +$2.41 million (+12.81%). AKTX annual CFO is now -4389.62% below its all-time high of -$366.00 thousand, reached on 31 December 2010.AKTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.49 M
+$3.40 M+69.55%
01 September 2024
Summary:
Akari Therapeutics quarterly cash flow from operations is currently -$1.49 million, with the most recent change of +$3.40 million (+69.55%) on 01 September 2024. Over the past year, it has increased by +$2.92 million (+66.21%). AKTX quarterly CFO is now -133.18% below its all-time high of $4.49 million, reached on 30 September 2015.AKTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$14.84 M
+$959.00 K+6.07%
01 September 2024
Summary:
Akari Therapeutics TTM cash flow from operations is currently -$14.84 million, with the most recent change of +$959.00 thousand (+6.07%) on 01 September 2024. Over the past year, it has increased by +$1.59 million (+9.71%). AKTX TTM CFO is now -1405.04% below its all-time high of $1.14 million, reached on 30 September 2015.AKTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +66.2% | +9.7% |
| 3 y3 years | +12.8% | +70.2% | +21.3% |
| 5 y5 years | -27.2% | +57.0% | -14.8% |
AKTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +23.6% | at high | +82.6% | -55.0% | +26.5% |
| 5 y | 5 years | -27.2% | +23.6% | -111.6% | +82.6% | -55.0% | +29.0% |
| alltime | all time | -4389.6% | +48.0% | -133.2% | +83.8% | -1405.0% | +53.0% |
Akari Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.49 M(-69.6%) | -$14.84 M(-6.1%) |
| June 2024 | - | -$4.89 M(+21.0%) | -$15.80 M(+1.3%) |
| Mar 2024 | - | -$4.04 M(-8.3%) | -$15.60 M(-5.1%) |
| Dec 2023 | -$16.43 M(-23.6%) | -$4.41 M(+80.0%) | -$16.43 M(+36.7%) |
| Sept 2023 | - | -$2.45 M(-47.8%) | -$12.02 M(+25.6%) |
| June 2023 | - | -$4.69 M(-3.8%) | -$9.57 M(-28.8%) |
| Mar 2023 | - | -$4.88 M(-43.1%) | -$13.45 M(-33.4%) |
| Dec 2022 | -$21.50 M(+14.1%) | - | - |
| June 2022 | - | -$8.57 M(+69.8%) | -$20.19 M(+22.5%) |
| Mar 2022 | - | -$5.05 M(+0.9%) | -$16.48 M(-12.6%) |
| Dec 2021 | -$18.85 M(+11.2%) | -$5.00 M(+221.0%) | -$18.85 M(+4.3%) |
| Sept 2021 | - | -$1.56 M(-68.0%) | -$18.08 M(+5.0%) |
| June 2021 | - | -$4.87 M(-34.4%) | -$17.22 M(+3.6%) |
| Mar 2021 | - | -$7.42 M(+75.2%) | -$16.63 M(-1.9%) |
| Dec 2020 | -$16.95 M(+31.2%) | -$4.23 M(+501.1%) | -$16.95 M(+4.8%) |
| Sept 2020 | - | -$704.20 K(-83.5%) | -$16.18 M(-20.6%) |
| June 2020 | - | -$4.27 M(-44.8%) | -$20.39 M(-2.4%) |
| Mar 2020 | - | -$7.74 M(+123.4%) | -$20.89 M(+61.7%) |
| Dec 2019 | -$12.92 M(-43.3%) | -$3.46 M(-29.4%) | -$12.92 M(-9.1%) |
| Sept 2019 | - | -$4.91 M(+2.9%) | -$14.22 M(-2.9%) |
| June 2019 | - | -$4.77 M(-2185.0%) | -$14.64 M(-19.3%) |
| Mar 2019 | - | $228.90 K(-104.8%) | -$18.15 M(-20.3%) |
| Dec 2018 | -$22.77 M | -$4.76 M(-10.7%) | -$22.77 M(-14.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$5.33 M(-35.6%) | -$26.53 M(-12.8%) |
| June 2018 | - | -$8.28 M(+88.4%) | -$30.41 M(+13.4%) |
| Mar 2018 | - | -$4.40 M(-48.4%) | -$26.83 M(-15.1%) |
| Dec 2017 | -$31.60 M(+28.3%) | -$8.52 M(-7.6%) | -$31.60 M(+6.8%) |
| Sept 2017 | - | -$9.21 M(+96.1%) | -$29.57 M(+16.6%) |
| June 2017 | - | -$4.70 M(-48.8%) | -$25.36 M(-3.8%) |
| Mar 2017 | - | -$9.17 M(+41.2%) | -$26.35 M(+7.0%) |
| Dec 2016 | -$24.62 M(+395.9%) | -$6.49 M(+29.9%) | -$24.62 M(-1.1%) |
| Sept 2016 | - | -$5.00 M(-12.2%) | -$24.90 M(+61.6%) |
| June 2016 | - | -$5.69 M(-23.5%) | -$15.41 M(+47.9%) |
| Mar 2016 | - | -$7.44 M(+9.9%) | -$10.42 M(+109.8%) |
| Dec 2015 | -$4.97 M(+236.2%) | -$6.77 M(-250.8%) | -$4.97 M(-536.8%) |
| Sept 2015 | - | $4.49 M(-743.9%) | $1.14 M(+433.3%) |
| June 2015 | - | -$697.50 K(-64.9%) | $213.20 K(-115.0%) |
| Mar 2015 | - | -$1.99 M(+197.7%) | -$1.42 M(-4.0%) |
| Dec 2014 | -$1.48 M(-72.9%) | -$668.00 K(-118.7%) | -$1.48 M(+82.6%) |
| Sept 2014 | - | $3.57 M(-253.2%) | -$808.80 K(-81.5%) |
| June 2014 | - | -$2.33 M(+13.7%) | -$4.38 M(+113.7%) |
| Mar 2014 | - | -$2.05 M | -$2.05 M |
| Dec 2013 | -$5.45 M(+155.4%) | - | - |
| Dec 2012 | -$2.13 M(+111.7%) | - | - |
| Dec 2011 | -$1.01 M(+175.4%) | - | - |
| Dec 2010 | -$366.00 K | - | - |
FAQ
- What is Akari Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Akari Therapeutics?
- What is Akari Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Akari Therapeutics?
- What is Akari Therapeutics quarterly CFO year-on-year change?
- What is Akari Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Akari Therapeutics?
- What is Akari Therapeutics TTM CFO year-on-year change?
What is Akari Therapeutics annual cash flow from operations?
The current annual CFO of AKTX is -$16.43 M
What is the all time high annual CFO for Akari Therapeutics?
Akari Therapeutics all-time high annual cash flow from operations is -$366.00 K
What is Akari Therapeutics quarterly cash flow from operations?
The current quarterly CFO of AKTX is -$1.49 M
What is the all time high quarterly CFO for Akari Therapeutics?
Akari Therapeutics all-time high quarterly cash flow from operations is $4.49 M
What is Akari Therapeutics quarterly CFO year-on-year change?
Over the past year, AKTX quarterly cash flow from operations has changed by +$2.92 M (+66.21%)
What is Akari Therapeutics TTM cash flow from operations?
The current TTM CFO of AKTX is -$14.84 M
What is the all time high TTM CFO for Akari Therapeutics?
Akari Therapeutics all-time high TTM cash flow from operations is $1.14 M
What is Akari Therapeutics TTM CFO year-on-year change?
Over the past year, AKTX TTM cash flow from operations has changed by +$1.59 M (+9.71%)